gemcitabine/carboplatin

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Taxol

Teva

Phase 3

2802

Navelbine

PPierre Fabre Medicament

Phase 3

243

gemcitabine/carboplatin

Sanofi

Phase 2

24

Remeron

OOrganon and Co

Preclinical

15

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—8

Treatment

GSK

Preclinical

19

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

210

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Completed·Sanofi·Phase 2·NCT00540358·123 enrolled

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

Unknown status·FFudan University·Phase 2·NCT02341911·150 enrolled

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Completed·Sanofi·Phase 3·NCT00938652·519 enrolled

Non-Small Cell Lung Cancer2 trials

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT02889666·500 enrolled

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Completed·TTongji University·Phase 3·NCT00874419·165 enrolled

Lung Cancer1 trial

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Completed·Sanofi·Phase 3·NCT01082549·780 enrolled

Bladder Cancer1 trial

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Active, not recruiting·AstraZeneca·Phase 2·NCT03775486·401 enrolled

1 more indication

Melanoma1 trial

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Completed·Eli Lilly·Phase 1·NCT02009449·353 enrolled

Details

Drug Info

Related News